{"entity":{"id":"idea-bio2-lymph-node-immune-priming","kind":"idea","name":"Treat the draining lymph node before removing it","aka":[],"tldr":"The first lymph node cancer reaches is also where the immune system learns to fight it. Injecting immunotherapy into that node before surgery, instead of removing it blindly, may work better.","summary":"Tumour-draining lymph nodes hold the stem-like precursor T cells that checkpoint blockade depends on, so removing or irradiating them may remove the substrate of response. Peritumoural or intranodal injection achieves high nodal exposure at a small fraction of the systemic dose, and small trials of peritumoural nivolumab in oral cancer and intratumoural ipilimumab in melanoma showed nodal immune activation.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Metastasis is understood least and studied last): Dillekås et al., Are 90% of deaths from cancer caused by metastases? (Cancer Medicine 2019)","url":"https://doi.org/10.1002/cam4.2474"}],"tags":[],"related":[],"cancers":["head-and-neck","melanoma"],"sections":[],"technologies":["checkpoint-inhibitor","sentinel-node"],"targets":[],"drugs":["nivolumab","ipilimumab"],"companies":[],"institutions":[],"pathways":[],"terms":["major-pathological-response","irae"],"trials":["checkmate-067","checkmate-238","checkmate-915","nadina","nivopostop"],"people":["christian-blank","john-haanen"],"bottlenecks":["b-metastasis-biology","b-tme-immunosuppression","b-toxicity-qol"],"keyPapers":["paper-dillekas-cancer-med","paper-hodi-ipilimumab-melanoma-nejm-2010","paper-nivolumab-melanoma-n-engl-j-med-2015","paper-keynote-006-pembrolizumab-ipilimumab-melanoma-nejm-2015"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Low-dose peritumoural or intranodal checkpoint blockade before surgery produces pathological response at least as good as systemic dosing, with fewer immune-related adverse events, in early oral cavity cancer and melanoma.","rationale":"Antigen presentation and T-cell priming happen in the node, not the tumour, while the dose-limiting toxicity of checkpoint blockade is systemic. Concentrating the drug where priming occurs is a pharmacology argument rather than a new mechanism.","test":"Randomised neoadjuvant window trial comparing low-dose peritumoural against standard intravenous checkpoint blockade, with major pathological response and nodal immune profiling as co-primary endpoints.","maturity":"early-clinical","actor":"clinic","cost":"medium","horizonYears":6},"route":"/ideas/idea-bio2-lymph-node-immune-priming/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"sentinel-node","kind":"technology","name":"Sentinel lymph node biopsy","route":"/technologies/sentinel-node/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"term":[{"id":"irae","kind":"term","name":"Immune-related adverse events (irAEs)","route":"/terms/irae/"},{"id":"major-pathological-response","kind":"term","name":"Major pathological response (MPR)","route":"/terms/major-pathological-response/"}],"trial":[{"id":"checkmate-067","kind":"trial","name":"CheckMate 067","route":"/trials/checkmate-067/"},{"id":"checkmate-238","kind":"trial","name":"CheckMate 238","route":"/trials/checkmate-238/"},{"id":"checkmate-915","kind":"trial","name":"CheckMate 915","route":"/trials/checkmate-915/"},{"id":"nadina","kind":"trial","name":"NADINA","route":"/trials/nadina/"},{"id":"nivopostop","kind":"trial","name":"NIVOPOSTOP (GORTEC 2018-01)","route":"/trials/nivopostop/"}],"person":[{"id":"christian-blank","kind":"person","name":"Christian Blank","route":"/people/christian-blank/"},{"id":"john-haanen","kind":"person","name":"John Haanen","route":"/people/john-haanen/"}],"bottleneck":[{"id":"b-tme-immunosuppression","kind":"bottleneck","name":"Cold tumours and the immunosuppressive microenvironment","route":"/bottlenecks/b-tme-immunosuppression/"},{"id":"b-metastasis-biology","kind":"bottleneck","name":"Metastasis is understood least and studied last","route":"/bottlenecks/b-metastasis-biology/"},{"id":"b-toxicity-qol","kind":"bottleneck","name":"Toxicity and quality of life are undervalued","route":"/bottlenecks/b-toxicity-qol/"}],"paper":[{"id":"paper-dillekas-cancer-med","kind":"paper","name":"Are 90% of deaths from cancer caused by metastases?","route":"/key-papers/paper-dillekas-cancer-med/"},{"id":"paper-nivolumab-melanoma-n-engl-j-med-2015","kind":"paper","name":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","route":"/key-papers/paper-nivolumab-melanoma-n-engl-j-med-2015/"},{"id":"paper-hodi-ipilimumab-melanoma-nejm-2010","kind":"paper","name":"Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma","route":"/key-papers/paper-hodi-ipilimumab-melanoma-nejm-2010/"},{"id":"paper-keynote-006-pembrolizumab-ipilimumab-melanoma-nejm-2015","kind":"paper","name":"KEYNOTE-006 (Robert 2015): pembrolizumab versus ipilimumab in advanced melanoma","route":"/key-papers/paper-keynote-006-pembrolizumab-ipilimumab-melanoma-nejm-2015/"}]}}